MYC and breast cancer: The demonstration that Ppm1d-deficient mice significantly delayed the formation of ERBB2-induced mammary tumors and that Ppm1d-null embryonic mouse fibroblasts were resistant to transformation by RAS, ERBB2, and c-MYC [27] encouraged us to establish a genetically modified mouse model overexpressing WIP1.